SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) or 2019-nCoV is a virus that triggers an ongoing outbreak of the lower respiratory tract disease known as coronavirus disease 2019 (COVID-19).
There have been over 111 million cases worldwide thus far, and the ongoing pandemic has led to an enormous amount of disruption in public health and safety.
The SARS-CoV-2 virus enters host cells by binding to the ACE2 receptor enzyme, because of this, effectively targeting the RBD-ACE2 interaction has the potential to open therapeutic avenues in the ongoing fight against the virus.
Conventional antibodies or immunoglobulins (IgG) are used as a means of therapeutic intervention, but a further subclass of IgGs from the camelid family with an unpaired heavy-chain domain has been found to facilitate competitive blocking of RBD-ACE2 binding.
This has the potential to provide a robust option for antibody-mediated therapies against the virus.
Nanobodies are a specific type of antibody found in sharks and llamas. Nanobodies possess a fully functional, biologically active heavy chain while lacking the light chain. This makes them different from conventional IgGs.
These heavy chain (only) antibodies are structured in such a way that they only include a single variable domain (Vhh) and two constant domains. In terms of research, llama nanobodies offer a number of advantages over conventional human antibodies.
They are less expensive to produce while presenting a far lower risk of the virus inadvertently gaining entry into immune cells.
Catalog number: C19S1-641HL
Product Description: Recombinant Llama VHH-Human IgG Antibody for high-sensitivity SARS-CoV-2 spike protein detection assays.
Scientists at SignalChem recently worked with a Canadian coalition team to develop llama nanobodies with the potential for use in the development of nanobody-based anti-COVID-19 therapeutics.
The Anti-2019-nCoV Spike Protein Llama Heavy chain Antibody is a recombinant VHH-Human IgG Antibody that has been generated in llamas.
These nanobodies are able to detect the 2019-nCoV spike protein in recombinant or biological samples. They have been comprehensively validated using functional ELISA and were found to successfully bind to the RBD domain of the SARS-CoV-2 Spike protein.
Figure 1. Binding ability measured in a functional ELISA. Immobilized Anti 2019-nCoV Spike Protein Llama heavy-chain (C19S1-641HL) binds 2019-nCoV Spike protein RBD (C19SD-241H) that can be detected at picomol level using Anti 2019-nCoV Spike Protein hIgG Antibody (C19S1-61H). Image Credit: SignalChem Biotech Inc.
Figure 2. Binding of Anti 2019-nCoV Spike Protein Llama heavy-chain (C19S1-641HL) to 2019-nCoV RBD (C19SD-G241H) determined by ELISA. Image Credit: SignalChem Biotech Inc.
SignalChem: A global leader in cell signaling
SignalChem is a world leader in protein engineering and cell signaling solutions. Since the initial COVID-19 outbreak, SignalChem has been conducting research and investing significant resources into better understanding the protein interaction map of the SARS-CoV-2.
The goal of this work has been to successfully engineer active recombinant SARS-CoV-2 and human proteins.
SignalChem is working to provide these important pieces of the puzzle to other researchers.
These proteins are essential components in drug discovery research projects worldwide, and through the use of advanced engineering technology and AI drug development software, SignalChem has already initiated a number of projects.
Current projects are ongoing, aiming to develop expression systems of key COVID-19 related proteins, such as hot drug targets including non-structural proteins (NSPs) and proteases.
Each of these catalytically active proteins is described as fully functional and is ready for use in research into the development of drugs targeted against SARS-CoV-2 and related coronavirus infections.
About SignalChem Biotech Inc.
SignalChem is a biotech company focused on the research, development, and production of innovative and high-quality human recombinant cell signaling products.
Throughout the years, Signalchem has capitalized on its core expertise in cellular signaling, molecular biology, and protein biochemistry to generate more than 2,000 functional protein products and has established itself as the leader in the industry to produce highly active human recombinant signaling enzymes, especially protein kinases, disease-related mutant kinases, lipid kinases, epigenetic enzymes, ubiquitination-related enzymes, and neurodegenerative disease-related enzymes and proteins.
SignalChem strives to support scientists in academia, pharma and biotech companies around the world by creating effective research tools to advance the basic research in life sciences and to facilitate the efforts in drug discovery and development.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.